Racetam

2-Pyrrolidone
Piracetam

Racetams are a class of drugs that share a pyrrolidone nucleus.[1] Some, such as piracetam, are considered nootropics. Some such as oxiracetam and phenylpiracetam are also stimulants. Others such as levetiracetam and seletracetam are anticonvulsants.

Mechanism

There is no universally accepted mechanism of action for racetams. Racetams generally show negligible affinity for common central nervous system receptors, but modulation of central neurotransmitters, including acetylcholine and glutamate, has been reported. Although aniracetam and nebracetam show affinity for muscarinic receptors, only nefiracetam demonstrates nanomolar interactions. Modification of membrane-located mechanisms of central signal transduction is another hypothesis.[2]

Like some ampakines, some racetams such as piracetam and aniracetam are positive allosteric modulators of the AMPA receptor.[3]

Racetams are understood to work by activating glutamate receptors that are colocalized with cholinergic receptors, thus increasing the frequency of activation of the latter.[4] Racetams are posited to enhance memory through interaction with cholinergic and glutamate receptors in the central nervous system.

Methylphenylpiracetam is a positive allosteric modulator of the sigma-1 receptor.[5]

Cofactors

In studies with aged rats, marked improvement has been observed in cognitive tasks in experimental groups given piracetam. Performance was further increased with piracetam combined with cholines. Evidence in studies with rats has indicated that the potency of piracetam is increased when administered with choline.[6]

References

  1. ↑ Löscher, W.; Richter, A. (2000). "Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia". European Journal of Pharmacology 391 (3): 251–254. doi:10.1016/S0014-2999(00)00105-9. PMID 10729365.
  2. ↑ Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Ghelardini, C. (2002). "Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs". Current pharmaceutical design 8 (2): 125–138. doi:10.2174/1381612023396582. PMID 11812254.
  3. ↑ Ahmed, A. H.; Oswald, R. E. (2010). "Piracetam Defines a New Binding Site for Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic Acid (AMPA) Receptors". Journal of Medicinal Chemistry 53 (5): 2197–2203. doi:10.1021/jm901905j. PMC 2872987. PMID 20163115.
  4. ↑ Copani, A.; Genazzani, A. A.; Aleppo, G.; Casabona, G.; Canonico, P. L.; Scapagnini, U.; Nicoletti, F. (1992). "Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures". Journal of Neurochemistry 58 (4): 1199–1204. doi:10.1111/j.1471-4159.1992.tb11329.x. PMID 1372342.
  5. ↑ Vavers E, Zvejniece L, Veinberg G, Svalbe B, Domracheva I, Vilskersts R, Dambrova M (2015). "Novel positive allosteric modulators of sigma-1 receptor". SpringerPlus 4: P51. doi:10.1186/2193-1801-4-S1-P51. The R-configuration enantiomers of methylphenylpiracetam are more active positive allosteric modulators of Sigma-1 receptor than S-configuration enantiomers.
  6. ↑ Bartus, R. T.; Dean Rl, 3.; Sherman, K. A.; Friedman, E.; Beer, B. (1981). "Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats". Neurobiology of Aging 2 (2): 105–111. doi:10.1016/0197-4580(81)90007-5. PMID 7301036.
This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.